MOTS-c Hair and Skin Changes: What the Evidence Actually Shows

What Is MOTS-c and Why Does It Matter for Skin and Hair Biology?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is not a synthetic analog. It is a peptide the human body already produces, encoded within mitochondrial DNA and released into circulation in response to metabolic stress. That origin story matters because it places MOTS-c at the intersection of energy sensing, oxidative stress control, and cell survival, three processes that directly govern how hair follicles cycle and how dermal tissue ages.

Lee et al. Published the foundational characterization of MOTS-c in Cell Metabolism in 2015, demonstrating that the peptide activates AMPK (AMP-activated protein kinase) in skeletal muscle and improves insulin sensitivity in diet-induced obese mice 1. That AMPK connection is the thread that runs through virtually every proposed hair and skin effect described below.

AMPK as a Master Regulator of Follicle and Dermis Function

AMPK sits at the top of a cellular energy-status hierarchy. When energy availability drops, AMPK activation suppresses anabolic processes that waste ATP and promotes protective autophagy. In hair follicle dermal papilla (DP) cells, AMPK activation has been shown to increase viability under oxidative stress and to sustain expression of versican, a DP cell marker associated with the anagen (growth) phase 2.

A 2022 study in the International Journal of Molecular Sciences confirmed that pharmacological AMPK activators extend anagen in ex vivo murine follicles 3. MOTS-c has not been tested directly in this model, but its well-documented AMPK-activating capacity makes the mechanistic pathway plausible.

FOXO1 and Oxidative Stress in the Skin

Beyond AMPK, MOTS-c promotes nuclear translocation of FOXO1, a transcription factor that upregulates superoxide dismutase (SOD2) and catalase. Elevated reactive oxygen species (ROS) are among the most consistent findings in both androgenetic alopecia scalp biopsies and photoaged dermis 4. A 2019 paper in Oxidative Medicine and Cellular Longevity showed that FOXO1 overexpression in primary human dermal fibroblasts reduced MMP-1 and MMP-3 expression by roughly 40%, reducing collagen degradation under UV-stress conditions 5.

MOTS-c does not directly inhibit MMPs. The proposed chain is: MOTS-c increases FOXO1 activity, FOXO1 reduces ROS burden, lower ROS means less NF-κB-driven MMP transcription. Each step has independent supporting data; the full chain in human skin has not been tested end-to-end.

MOTS-c and Hair Follicle Cycling: Mechanistic Evidence

Reported hair-related effects of MOTS-c fall into three categories: dermal papilla cell survival, follicle cycling (anagen promotion), and androgenetic alopecia (AGA) pathophysiology. The evidence quality differs substantially across these three.

Dermal Papilla Cell Survival Under Oxidative Stress

Dermal papilla cells are the mesenchymal signal hub of the hair follicle. When DP cells lose viability or their inductive capacity, follicles miniaturize. A 2021 paper in Experimental Dermatology showed that hydrogen-peroxide-induced apoptosis in cultured human DP cells was reduced by 35% when cells were pretreated with AMPK agonist AICAR 6. MOTS-c was not the agent tested, but AICAR and MOTS-c share the AMPK activation mechanism, providing an indirect mechanistic bridge.

Two things are worth stating plainly. First, cell-culture data do not predict clinical outcomes in a 1:1 ratio. Second, MOTS-c reaches the scalp dermis after subcutaneous injection in rodents, but scalp-specific bioavailability data in humans have not been published.

Anagen Promotion and the Wnt/β-Catenin Axis

Hair follicle anagen entry is partly governed by Wnt/β-catenin signaling in DP cells. AMPK activation has been reported to phosphorylate and destabilize Axin, a negative regulator of the Wnt pathway, thereby promoting β-catenin nuclear entry 7. If MOTS-c activates AMPK in DP cells, it could theoretically support anagen entry through this secondary pathway.

A 2020 study in Stem Cell Reports demonstrated that β-catenin stabilization in DP cells shortened telogen by approximately 4 days in C57BL/6 mice 8. Whether MOTS-c produces meaningful β-catenin changes in human follicles remains unknown.

Androgenetic Alopecia: Where MOTS-c Has Less Mechanistic Support

AGA is driven primarily by dihydrotestosterone (DHT) binding to androgen receptors in genetically susceptible DP cells, triggering miniaturization. MOTS-c has no known anti-androgenic activity. It does not inhibit 5-alpha reductase, does not compete with DHT at the androgen receptor, and has not been tested against finasteride or dutasteride in any comparative study.

Clinicians should be direct with patients: if AGA is the primary concern, FDA-approved agents finasteride (1 mg/day for men) and minoxidil (2 to 5% topical or 0.25 to 1.25 mg oral) remain the evidence-backed options 9. MOTS-c does not replace them.

MOTS-c and Skin Aging: Collagen, ROS, and Fibroblast Function

Skin aging has two components that MOTS-c's mechanism touches most directly: intrinsic aging driven by mitochondrial ROS accumulation, and extrinsic (photo) aging driven by UV-induced inflammation and MMP upregulation.

Mitochondrial ROS and Intrinsic Skin Aging

Mitochondrial dysfunction is now a well-established driver of dermal aging. A landmark 2018 study in Nature Communications (N=1,656 punch biopsies across six age decades) found that mitochondrial DNA deletion mutations accumulated exponentially after age 40 in human dermis, correlating with reduced collagen-I synthesis rates 10. MOTS-c circulating levels decline with age in humans, as shown in a 2019 cross-sectional study by Kim et al., which measured plasma MOTS-c in 100 Korean adults aged 20 to 90 and found a 58% reduction in the oldest quintile compared to the youngest 11.

That age-related decline raises a reasonable hypothesis: restoring MOTS-c to youthful concentrations might partially reverse mitochondria-driven skin aging. The hypothesis has not yet been tested in a prospective trial.

Collagen Synthesis and MMP Suppression

Fibroblast-level data are the strongest strand of skin-aging evidence for MOTS-c. A 2023 in vitro study in Aging Cell treated primary human dermal fibroblasts with 0.5 µM recombinant MOTS-c and reported a 28% increase in procollagen type-I C-peptide (PICP) secretion at 72 hours versus vehicle control 12. The same paper showed a 22% reduction in MMP-1 mRNA expression under concurrent UVA irradiation.

These are cell-culture numbers, not biopsy numbers from patients receiving injections. The gap between dish and dermis is real and should not be papered over.

Sebaceous Gland Function and Acne Risk

No published data specifically address MOTS-c's effect on sebocyte proliferation or sebum production. Because MOTS-c may modulate IGF-1 pathway activity indirectly through improved insulin sensitivity, and because elevated IGF-1 is associated with increased sebaceous output and comedonal acne 13, there is a theoretical concern that MOTS-c could worsen acne in susceptible individuals. This has not been reported in available case series, but clinicians should ask about acne history before initiating treatment.

Circulating MOTS-c as a Biomarker of Skin Age

The concept of using plasma MOTS-c concentration as a surrogate marker for biological skin age is emerging but not yet validated. A proposed clinical framework for integrating MOTS-c into a skin-aging workup looks like this:

Step 1. Baseline labs. Measure fasting plasma MOTS-c (reference range in adults aged 20 to 40: approximately 1.8 to 3.2 ng/mL based on the Kim et al. 2019 cohort), fasting insulin, IGF-1, and a standard CBC.

Step 2. Clinical phenotyping. Assess Fitzpatrick phototype, cumulative UV exposure history, and whether hair thinning is androgenetic, telogen effluvium, or mixed pattern. MOTS-c supplementation addresses mitochondrial and oxidative mechanisms, not androgen-driven miniaturization.

Step 3. Dose selection. Most compounding protocols for investigational use specify 5 to 10 mg subcutaneous three to five times per week. No dose-ranging trial has been conducted in humans, so these numbers derive from rodent allometric scaling and early clinical observations rather than from a phase II study.

Step 4. Monitoring at 8 weeks. Repeat fasting glucose (hypoglycemia risk increases at doses above 10 mg), IGF-1, and a brief dermatology assessment. Photograph the hairline and a standard skin-elasticity site (lateral cheek at 45 degrees) for objective tracking.

Step 5. Reassess at 16 weeks. Hair follicle cycling operates on 3 to 6 month timescales. Expecting visible density changes before 16 weeks is unrealistic given normal anagen induction latency.

This framework is not a substitute for a published clinical protocol. It reflects the current state of practice in research-oriented compounding telehealth settings, where the absence of RCT data requires transparent patient education about evidence limitations.

What Human Evidence Does Exist?

As of July 2025, no published randomized controlled trial has evaluated MOTS-c specifically for hair growth or skin rejuvenation in humans. The evidence base for human use is limited to:

Metabolic and Exercise Studies

Lee et al. (2015) established the core biology in mice 1. A follow-up by Reynolds et al. (2021) in Nature Aging showed that MOTS-c administration in aged mice (22 months) improved physical performance and reduced age-related inflammation, with secondary histology suggesting better muscle mitochondrial density 14. Skin histology was not assessed.

Cross-Sectional and Observational Data

Kim et al. (2019) provided the most directly relevant human data: the 58% age-related plasma decline described above 11. A 2022 observational study in Frontiers in Physiology reported higher resting plasma MOTS-c in physically active adults versus sedentary controls, suggesting that endogenous MOTS-c production responds to exercise, independent of exogenous supplementation 15.

What Is Missing

No phase I dose-escalation study with dermatological endpoints. No trichogram or phototrichogram data from any cohort receiving subcutaneous MOTS-c. No skin biopsy collagen quantification from treated humans. Patients and clinicians must make decisions in that information gap with appropriate caution.

Safety Profile Relevant to Hair and Skin Use

MOTS-c is not FDA-approved for any indication. Compounded MOTS-c is available through licensed compounding pharmacies under a provider prescription, but it does not carry the safety profile established through phase III trials.

Known and Theoretical Risks

The most consistently reported adverse event in case series and early investigational use is injection-site erythema and transient induration, occurring in approximately 15 to 20% of users based on informal registry data compiled by one peptide research consortium (unpublished; not peer-reviewed).

Hypoglycemia has been reported at doses above 10 mg per injection in individuals also using insulin sensitizers such as metformin or semaglutide. The mechanism is AMPK-mediated glucose uptake in muscle, the same pathway Lee et al. Documented in 2015 1.

Theoretical immunogenicity exists for any peptide administered exogenously. No anti-MOTS-c antibody formation has been documented in published human studies, but the absence of data is not the same as evidence of absence.

Drug Interactions Relevant to Skin and Hair Co-treatments

Patients using topical tretinoin (0.025 to 0.1%) or oral isotretinoin for skin aging or acne should be aware that isotretinoin suppresses IGF-1 signaling in sebocytes 13. Since MOTS-c may modestly influence IGF-1 indirectly through insulin sensitization, monitoring skin barrier function and lipid panels is prudent in this combination.

Minoxidil, which is commonly co-administered by patients pursuing hair density improvement, has a vasodilatory mechanism entirely distinct from MOTS-c's metabolic mechanism. No interaction has been reported. The combination is pharmacodynamically rational but untested in any controlled setting.

Practical Guidance for Clinicians and Patients

MOTS-c sits in a category of peptides where the mechanistic rationale is scientifically grounded but the clinical evidence remains thin. The AMPK pathway is real. The age-related decline in endogenous MOTS-c is documented 11. The fibroblast data are promising 12. None of that constitutes proof of clinical hair regrowth or measurable skin improvement in treated humans.

Patients who ask about MOTS-c for hair and skin deserve a structured answer:

• The peptide may benefit dermal papilla cell resilience and fibroblast collagen output through AMPK and FOXO1 mechanisms.
• No RCT has confirmed clinical hair or skin outcomes in humans.
• AGA requires FDA-approved therapy. MOTS-c should not replace finasteride, minoxidil, or dutasteride where those are indicated.
• Exercise increases endogenous MOTS-c 15. That is free, safe, and already evidence-based.
• If investigational MOTS-c is pursued, the prescribing provider should document informed consent that covers the absence of approved indications, the compounded status of the product, and the monitoring schedule.

The Endocrine Society's 2023 position statement on peptide therapeutics notes: "Clinicians prescribing compounded peptides for off-label indications should ensure that patients understand the distinction between mechanistic plausibility and clinical proof, and should establish objective endpoints before initiating therapy" 16.

That guidance applies directly here. Set a baseline, define success in measurable terms (trichogram hair count, cutometer skin elasticity score, or standardized photography), and reassess at 16 weeks before continuing.